CALT News and Press, Calliditas Therapeutics AB From 12/16/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips FREYR Battery (NYSE: FREY ) stock is soaring higher on Thursday thanks to a 31 GWh deal for its low-carbon battery cells. Source: asharkyu / Shutterstock.com Here’s everything investors in FREY stock n...

Gainers: Adagio Therapeutics (NASDAQ:ADGI) +68%, Calliditas Therapeutics (NASDAQ:CALT) +28%, Assertio (NASDAQ:ASRT) +17%, Aptose Biosciences (NASDAQ:APTO) +16%, Arcturus Therapeutics (NASDAQ:ARCT) +15%. Losers: uniQure (NASDAQ:QURE) -25%, Regi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evercore ISI analyst Kirk Materne recently weighed in on the tech sector and named three software stocks that are ready for a rebound. Source: Shutterstock According to the analyst, there are underperformers in the ...

Calliditas Therapeutics (NASDAQ:CALT) +38% on FDA approval for kidney disease therapy. Kaixin Auto (NASDAQ:KXIN) +27% on a partnership agreement with Bujia for 10k new energy trucks. Biomerica (NASDAQ:BMRA) +18% preliminary second quarter revenue increase of approxima...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re getting right into the swing of things with a breakdown of the biggest pre-market stock movers for Thursday! Source: Shutterstock We’ve got an FDA update, several agreements...

Calliditas Therapeutics (NASDAQ:CALT) +67%. Recursion Pharmaceuticals (NASDAQ:RXRX) +10%. Verrica Pharmaceuticals (NASDAQ:VRCA) +9%. Qorvo (NASDAQ:QRVO) +6%. Sharecare (NASDAQ:SHCR) +5%. Blue Bird (NASDAQ:BLBD) -10%. Freshworks (NASDAQ:FRSH) -4%. Nutanix (NASDAQ:NTNX) -4%. Cumberland Pharmace...

FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy - TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults with primary IgA nephropathy...

Calliditas Therapeutics (NASDAQ:CALT) ADRs have climbed in the post-market after the company announced the FDA approval of TARPEYO (budesonide) to address proteinuria in adults with primary immunoglobulin A nephropathy ((IgAN)). FDA clearance for TARPEYO delayed-release capsules tra...

Calliditas Therapeutics: Interim Report Q3, 2021 A quarter of deal making and regulatory review PR Newswire STOCKHOLM , Nov. 18, 2021 /PRNewswire/ -- "Following on from the positive top line read out of Part A our Phase 3 study, we initiated a structured proc...

Calliditas announces poster presentations at ASN Digital Kidney Week 2021 PR Newswire STOCKHOLM , Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning N...